Bay Area biotechs soar on coattails of AstraZeneca cancer drug study

The companies have drugs in clinical trials that target an enzyme implicated in poor prognosis for patients.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.